Randomized Phase II Study of Pemetrexed Versus Pemetrexed and Carboplatin as Second Line Chemotherapy in Advanced Non-small-cell Lung Cancer (NSCLC).
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 230
- 试验地点
- 21
- 主要终点
- To compare time to progression between the combination pemetrexed-carboplatin and pemetrexed alone in previously treated patients with locally advanced or metastatic NSCLC
研究概览
简要总结
The aim of this study is to compare time to progression between the combination pemetrexed-carboplatin and pemetrexed alone in previously treated patients with locally advanced or metastatic NSCLC.
详细描述
In spite of the superiority of single agent over best supportive care in second-line NSCLC, the prognosis of these patients remains poor with a median survival of 6-7 months, justifying the evaluation of new regimens in this setting. An open question in the second-line treatment of NSCLC remains the possible superiority of combination chemotherapy over single agent, as it has been clearly demonstrated in first-line. Particularly, the addition of platinum to either docetaxel or pemetrexed should be further investigated especially in patients with prior response/stable disease to platinum-based first-line chemotherapy. Pemetrexed has shown anti-tumor activity in combination with other chemotherapy agents, including gemcitabine, vinorelbine, taxanes, cisplatin and carboplatin. In this multicenter, open label, randomized phase II trial, pemetrexed 500 mg/m2 and carboplatin AUC 5 will be administered on day 1 every 3 weeks until progression of disease or for a maximum of 4 courses in the experimental arm. The control arm will be pemetrexed as single agent at 500 mg/m2 on day 1 every 3 weeks until progression of disease or for a maximum of 4 courses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •written informed consent
- •Histologically or cytologically confirmed non-small-cell lung cancer
- •Unresectable stage IIIB, stage IV and unresectable local relapse or metastatic disease, with evidence of disease progression after first line chemotherapy which should have included a platinum agent.
- •ECOG performance status lower than or equal to 2
- •Adequate hematological, hepatic and renal functions
- •Life expectancy greater than or equal to 12 weeks
- •Prior treatment with only 1 chemotherapy regimen for the treatment of advanced disease which should have included a platinum agent
- •At baseline, presence of at least one measurable target lesion as per RECIST criteria
排除标准
- •Prior treatment with pemetrexed.
- •Patients who are pregnant or lactating
- •Patients with any underlying medical condition that might be aggravated by treatment or which cannot be controlled.
- •Symptomatic brain metastases
- •History of another malignancy within the past five years except basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- •Concomitant treatment with any other anticancer drug.
研究组 & 干预措施
A
Monochemotherapy
干预措施: Pemetrexed (Drug)
B
Combination chemotherapy
干预措施: Pemetrexed plus carboplatin (Drug)
结局指标
主要结局
To compare time to progression between the combination pemetrexed-carboplatin and pemetrexed alone in previously treated patients with locally advanced or metastatic NSCLC
时间窗: 36 months
次要结局
- To assess differences in terms of response rate between the combination pemetrexed-carboplatin and pemetrexed alone.(3 months)
- To assess differences in terms of duration of response between the combination pemetrexed-carboplatin and pemetrexed alone.(36 months)
- To assess differences in terms of toxicity between the combination pemetrexed-carboplatin and pemetrexed alone.(3 months)
- To assess differences in terms of survival between the combination pemetrexed-carboplatin and pemetrexed alone.(36 months)